• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

byMinjee Kim
August 10, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular death, hospitalization for heart failure and the kidney-specific composite outcome.

2. In patients receiving angiotensin converting enzyme inhibitors or angiotensin-receptor blockers with both β-blockers and diuretics, dapagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure by 24% and kidney-specific composite outcome by 38%.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule of the kidneys and promotes glucosuria. This class of medication has been proven to reduce cardiovascular (CV) events and kidney disease progression, specifically in patients with type 2 diabetes. In this prespecified secondary analysis of the DECLARE-TIMI 58 trial, the objective was to assess whether cardiorenal efficacy and safety of dapagliflozin were consistent with, and without CV medication use in the background. The DECLARE-TIMI 58 trial was a randomized trial of dapagliflozin vs placebo among 17,160 patients with type 2 diabetes, and either atherosclerotic disease or multiple CV disease risk factors. Patients in this study were stratified by their baseline use of: angiotensin converting enzyme inhibitors or angiotensin-receptor blockers (ACEi/ARBs), β-blockers, diuretics, and mineralocorticoid receptor antagonists (MRAs), all medications commonly used for heart failure (HF) and kidney disease in patients with type 2 diabetes. The main outcomes were composite of CV death or hospitalization for HF, hospitalization for heart failure (HHF) alone, and a kidney specific composite outcome. Among 17,160 patients, dapagliflozin consistently reduced the risk of CV death/HHF, HHF alone and the kidney-specific composite outcome, regardless of use of background medications. In patients receiving ACEi/ARBs with both β-blockers, and diuretics, dapagliflozin reduced the risk of CV death/HHF and kidney-specific composite outcome by 24%, and 38%, respectively. This timely analysis demonstrated that the safety profile of dapagliflozin was consistent in patients regardless of their CV medication use. A limitation of the study was that since the dose of each medication was not recorded, treatment interactions across a range of doses could not be examined.

Click to read the study in JAMA Cardiology

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

Relevant Reading: Dapagliflozin and cardiovascular outcomes in type 2 diabetes

In-Depth [randomized clinical trial]: This study is a prespecified secondary analysis of the randomized clinical trial DECLARE-TIMI 58 conducted between 2013 to 2018, which compared dapagliflozin vs placebo among 17,160 patients with type 2 diabetes and either atherosclerotic disease or multiple CVD risk factors. Among the 17,160 patients, 13,950 (81%) used ACEi/ARBs, 9030 (53%) used β-blockers, 6205 (36%) used diuretics, and 762 (4%) used MRAs at baseline. Blood pressure and eGFR changes did not differ at 48 months with dapagliflozin vs placebo, regardless of concurrent therapy (placebo-corrected change, -1.6mmHg [95% CI, -4.2 to 1.0] to -2.6mmHg [95% CI, -3.3 to -2.9]; P > .05 for each interaction). Dapagliflozin consistently reduced the risk of CV death/HHF, and kidney-specific composite outcome irrespective of the background use of CV medications including ACEi/ARBs, β-blockers, diuretics, and MRAs (hazard ratio [HR] range: HR, 0.50; 95% CI, 0.39-0.63; to HR, 0.82; 95% CI, 0.72-0.95; P > .05 for each interaction). In patients who were concurrently on all the following medications: ACEi/ARBs, β-blockers and diuretics (n= 4243), dapagliflozin reduced the risk of CV death/HHR and kidney specific outcomes by 24% (HR, 0.76; 95% CI, 0.62-0.93) and 38% (HR, 0.62; 95% CI, 0.44-0.87), respectively. Dapagliflozin consistently reduced the risk of kidney specific composite outcome regardless of the concurrent use of CV medications except for diuretics (P > .05 for each interaction). In terms of the safety profile for serious adverse events, no significant treatment interactions were found for concurrent CV medication use for adverse events of volume depletion, acute kidney injury, or hyperkalemia (range: HR, 0.12; 95% CI, 0.02-0.99; to HR, 1.04; 95% CI, 0.83-1.32; P > .05 for each interaction).

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aceiarbb-blockersBeta-blockerscardiovascularCVD risk factorsdapagliflozinDECLARE-TIMI 58diabetesdiureticsfurosemideheart failurehypertensionMRAstype 2 diabetes
Previous Post

Nonsteroidal Anti-Inflammatory Drug exposure associated with development of microscopic colitis

Next Post

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

#VisualAbstract: Addition of selumetinib to radioactive iodine does not improve remission rates in differentiated thyroid cancers

#VisualAbstract: Addition of selumetinib to radioactive iodine does not improve remission rates in differentiated thyroid cancers

Non-invasive ventilation linked with lower mortality in COPD exacerbations

Racial differences exist in emphysema prevalence in adults with normal spirometry findings

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.